Staphylococcus aureus Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) (MSCRAMMs)

Staphylococcus aureus Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) are a family of cell wall-anchored proteins that mediate the initial attachment of bacteria to host tissues and medical implants. These proteins, such as Fibronectin-binding proteins (FnBPs) and Clumping factors (ClfA/B), specifically recognize and bind to host extracellular matrix (ECM) and plasma proteins like fibrinogen, fibronectin, and collagen. This interaction is a critical first step in the pathogenesis of invasive infections, allowing the bacteria to colonize surfaces, evade the immune system, and internalize into host cells. Beyond initial attachment, these proteins are essential for the formation and stabilization of biofilms, which protect the bacteria from both host immune responses and antibiotic treatment. In the context of drug development, the interaction between MSCRAMMs and host proteins is a high-priority target for anti-virulence and anti-biofilm therapies. By inhibiting these interactions, researchers aim to prevent the establishment of chronic infections and increase the susceptibility of S. aureus to conventional antibiotics. Current approaches include the development of monoclonal antibodies to neutralize specific adhesins and small molecules that inhibit Sortase A, the transpeptidase responsible for anchoring MSCRAMMs to the bacterial peptidoglycan. Despite their potential, the high degree of functional redundancy among different staphylococcal surface proteins remains a significant challenge for achieving complete therapeutic efficacy.

Other names

S. aureus biofilm-associated proteinsStaphylococcal adhesinsBacterial surface proteinsHost-pathogen interaction complexBiofilm-associated protein (Bap)Fibronectin-binding proteins (FnBPA/FnBPB)Fibrinogen-binding proteins (ClfA/ClfB)Collagen-binding protein (Cna)

Therapeutic strategies include monoclonal antibodies that block the binding of MSCRAMMs to host ligands (e.g., fibrinogen or fibronectin), small molecule inhibitors of sortase A (the enzyme that anchors these proteins to the cell wall), and anti-biofilm agents that disrupt the established proteinaceous matrix.